ClinicalTrials.gg

Program

carbidopa, levodopa drug combination

Also written as “IPX066”, “Sinemet®” and “Levodopa-Carbidopa Intestinal Gel (LCIG)”.

Its studies are mostly in Parkinson Disease · Dyskinesias, led by 6 companies.

Furthest: phase 4, since Apr 3, 200918 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amneal Pharmaceuticals60 open or runningphase 3since Apr 3, 2009Mar 24, 2009none ahead
AbbVie40 open or runningphase 4since Aug 30, 2005Aug 30, 2005none ahead
Orion Corporation, Orion Pharma40 open or runningphase 2since Nov 19, 2007Nov 19, 2007none ahead
UCB20 open or runningphase 3since Aug 29, 2005Aug 29, 2005none ahead
Hong Kong WD Pharmaceutical10 open or runningphase 1since Nov 26, 2018Nov 26, 2018none ahead
Tanabe Pharma10 open or runningphase 1since Jun 22, 2015Jun 22, 2015none ahead

Also a collaborator on its studies: TFS Trial Form Support and Abbott Japan.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 4 studies since Aug 29, 2005.

  1. Apr 15, 2008Phase 3 study in Parkinson DiseaseAbbVie · NCT00660673 · 262 enrolled · United States, Australia, Canada and more
  2. Mar 24, 2009Amneal Pharmaceuticals’ first study: phase 2 study in Parkinson DiseaseNew to Amneal PharmaceuticalsAmneal Pharmaceuticals · NCT00869791 · 27 enrolled · United States
  3. Apr 3, 2009Phase 3 study in Parkinson DiseaseAmneal Pharmaceuticals · NCT00880620 · 381 enrolled · United States, Canada, Estonia and more
  4. Sep 10, 2009Phase 3 study in Parkinson DiseaseAmneal Pharmaceuticals · NCT00974974 · 471 enrolled · United States, Canada, France and more
  5. Mar 25, 2010Phase 3 study in Parkinson DiseaseAmneal Pharmaceuticals · NCT01096186 · 617 enrolled · United States, Canada, Estonia and more
  6. May 24, 2010Phase 3 study in Parkinson DiseaseAmneal Pharmaceuticals · NCT01130493 · 110 enrolled · United States, France, Germany and more
  7. Aug 4, 2011Phase 3 study in Parkinson DiseaseAmneal Pharmaceuticals · NCT01411137 · 43 enrolled · United States
  8. Sep 26, 2011Phase 2 study in DyskinesiasAbbVie · NCT01479127 · 8 enrolled
  9. Dec 2, 2014Phase 1 study in Parkinson DiseaseOrion Corporation, Orion Pharma · NCT02312232 · 20 enrolled · Finland
  10. Jun 10, 2015Phase 1 study in Parkinson DiseaseOrion Corporation, Orion Pharma · NCT02554734 · 15 enrolled · Finland
  11. Jun 22, 2015Tanabe Pharma’s first study: phase 1 study in Parkinson DiseaseNew to Tanabe PharmaTanabe Pharma · NCT02486432 · 6 enrolled
  12. Jun 10, 2016Phase 3 study in Parkinson DiseaseAbbVie · NCT02799381 · 63 enrolled · United States, Finland, Greece and more
  13. Apr 12, 2017Phase 1 study in Parkinson DiseaseOrion Corporation, Orion Pharma · NCT03140956 · 20 enrolled · Finland
  14. Nov 26, 2018Hong Kong WD Pharmaceutical’s first study: phase 1 study in Healthy VolunteersNew to Hong Kong WD PharmaceuticalHong Kong WD Pharmaceutical · NCT03761004 · 8 enrolled · Canada

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 18 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT03761004Healthy Volunteers · Canada1CompletedHong Kong WD PharmaceuticalSep 5, 20198
NCT03140956Parkinson Disease · Finland1CompletedOrion Corporation, Orion PharmaJul 3, 201720
NCT02799381Parkinson Disease · United States, Finland, Greece and more3CompletedAbbVieSep 19, 201963
NCT02486432Parkinson Disease1CompletedTanabe PharmaApr 20156
NCT02554734Parkinson Disease · Finland1CompletedOrion Corporation, Orion PharmaNov 201515
NCT02312232Parkinson Disease · Finland1CompletedOrion Corporation, Orion PharmaFeb 201520
NCT01479127Dyskinesias2CompletedAbbVieJul 20128
NCT01411137Parkinson Disease · United States3CompletedAmneal PharmaceuticalsMar 201343
NCT01130493Parkinson Disease · United States, France, Germany and more3CompletedAmneal PharmaceuticalsJan 2012110
NCT01096186Parkinson Disease · United States, Canada, Estonia and more3CompletedAmneal PharmaceuticalsOct 2011617
NCT00974974Parkinson Disease · United States, Canada, France and more3CompletedAmneal PharmaceuticalsJan 2011471
NCT00880620Parkinson Disease · United States, Canada, Estonia and more3CompletedAmneal PharmaceuticalsOct 2010381
NCT00869791Parkinson Disease · United States2CompletedAmneal PharmaceuticalsJun 200927
NCT00660673Parkinson Disease · United States, Australia, Canada and more3CompletedAbbVieNov 30, 2021262
NCT00562198Parkinson Disease · Finland2TerminatedOrion Corporation, Orion PharmaFeb 200816
NCT00141518Advanced Idiopathic Parkinson's Disease4CompletedAbbVieMar 201177
NCT00139880Parkinson Disease · United States3CompletedUCBAug 2005
NCT00139867Parkinson Disease · United States3CompletedUCBMay 2004

How it is read

Names in the registry

  • “IPX066”, 4 entries
  • “Sinemet®”, 3 entries
  • “Levodopa-Carbidopa Intestinal Gel (LCIG)”, 2 entries
  • “levodopa, carbidopa, ODM-104”, 2 entries
  • “HRG2010 Capsule, Sinemet®, Madopar®”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.